Tradolgesic

Quick links to important sections

Tradolgesic

Treatment option: Pain, Chronic Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tradolgesic

Quick Facts

Property Description
Active Ingredient Tramadol Hydrochloride (C16H25NO2 cdot HCl)
Form Oral tablets/capsules, oral solution, and parenteral solution
Pharmacological Class Centrally acting synthetic opioid analgesic
General Purpose Management of moderate to severe pain
Origin Synthetic compound

Tradolgesic: Definition and Pharmacological Classification

Tradolgesic is a pharmaceutical preparation whose primary active component is Tramadol Hydrochloride, a substance utilized for pain management. This medicine is classified as a centrally acting synthetic opioid analgesic, a group of medications that achieve their effect by working within the central nervous system, specifically the brain and spinal cord, rather than locally. Tramadol is used to relieve moderate to severe pain, addressing discomfort levels that are typically substantial and unlikely to respond adequately to non-opioid options.

Composition, Forms, and General Therapeutic Purpose

The fundamental identity of Tradolgesic is rooted in the synthetic chemical entity Tramadol Hydrochloride, a single active ingredient product that is not derived from natural poppy extracts. A key differentiating feature is its dual-acting mechanism, which involves both engagement with opioid receptors and the modulation of the neurotransmitters norepinephrine and serotonin. This dual action distinguishes it from classic opioid analogues, which primarily target mu-opioid receptors. This structure allows the medication to influence pain perception via multiple chemical pathways. Tradolgesic is supplied in diverse dosage forms, including oral solid preparations, an oral solution, and a parenteral solution for injection, facilitating administration via the oral or parenteral route to provide systemic relief.

Regulatory References

  1. Tramadol: MedlinePlus Drug Information
  2. MedlinePlus - Tramadol Drug Information

What side effects are possible with Tradolgesic?

Possible Side Effects and Safety Information

The safety profile for Tradolgesic (Tramadol Hydrochloride) is officially documented according to regulatory frequency classifications and the body systems affected. These classifications communicate the likelihood of adverse reactions based on clinical data and post-marketing reports.


Frequency-Classified Adverse Reactions

The following are classified by regulatory authorities based on their typical occurrence rate:

Frequency Examples of Officially Listed Effects
Very Common (ge 1/10) Nausea, Dizziness/Vertigo
Common (ge 1/100 to < 1/10) Headache, Somnolence, Vomiting, Constipation, Dry mouth, Sweating, Fatigue
Uncommon (ge 1/1,000 to < 1/100) Cardiovascular changes (e.g., Postural hypotension), Gastrointestinal discomfort, Dermal reactions (e.g., Rash, Pruritus)
Rare (ge 1/10,000 to < 1/1,000) Respiratory depression, Seizures, Syncope, Allergic reactions (Anaphylaxis)

These effects are grouped into System-Organ Classes which include Nervous System, Gastrointestinal, Psychiatric, and Cardiovascular disorders.


Serious Adverse Reactions and Safety Constraints

Official labeling defines several serious adverse reactions and critical safety constraints. Life-threatening Respiratory Depression is a major concern, with the highest risk noted during the initiation of therapy or following a dose increase. The potential for Seizures and a life-threatening reaction known as Serotonin Syndrome is explicitly documented.

Additionally, the risk for Opioid Addiction, Abuse, and Misuse is a defined safety constraint. Regulatory documents also caution that use in certain groups, such as children under 12 years of age, is contraindicated, and special consideration is required for older adults (over 75 years) and individuals with hepatic or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Tradolgesic (Tramadol Hydrochloride) requires immediate medical attention and transfer to a specialised unit. The documented manifestations of intoxication are similar to those of other centrally acting opioid analgesics. These include miosis (pinpoint pupils), vomiting, and a range of consciousness disorders that may progress to coma. Severe, life-threatening outcomes include respiratory depression up to respiratory arrest, as well as cardiovascular collapse and the specific risk of convulsions or seizures. Serotonin Syndrome is also documented as a potentially life-threatening complication.

Immediate emergency medical care is strictly mandated for any suspected overdose. Management involves crucial supportive measures, including the reestablishment of a patent airway and institution of assisted ventilation to maintain vital functions. The opioid antagonist Naloxone is used to reverse respiratory depression; however, official regulatory documentation states that Naloxone may only partially reverse the full effects of Tramadol and explicitly warns that its use increases the risk of convulsions. Accidental ingestion, particularly by children, has resulted in fatal overdose, and close monitoring is required for ultra-rapid metabolizers.

Therapeutic Uses of Tradolgesic

What Tradolgesic Treats: Main Uses and Benefits

The fundamental purpose of Tradolgesic is to provide supportive symptomatic relief for pain that has reached a high level of intensity, particularly in situations where symptoms related to physical discomfort may not respond adequately to initial support. This medication is generally indicated for easing severe pain and is considered relevant in contexts where additional management of discomfort is required.

Addressing Moderate to Severe Acute Discomfort

This medication is commonly used for the management of pain episodes characterized by substantial, sudden, or pervasive discomfort, such as following a surgical procedure or a serious injury. It is relevant in clinical settings that require supportive assistance to address high-level symptoms. The primary benefit provides supportive relief that helps with pervasive physical discomfort and may assist with easing distressing manifestations during the acute phase. Common indications include acute postoperative pain, trauma-related pain, and pain associated with severe, temporary symptoms.

“It is applied to offer symptomatic support for individuals whose pain is substantial enough to disrupt daily stability.”

Managing Persistent Chronic Pain Syndromes

Tradolgesic is also commonly used for the management of persistent discomfort associated with chronic conditions, including musculoskeletal pain from illnesses like osteoarthritis and chronic low back pain. For these conditions, the medication may be relevant in situations that require continuous symptomatic support. This contributes to improved patient comfort and stability by helping to ease the impact of persistent symptoms on day-to-day functional abilities, especially when symptoms are classified as moderate to severe and are refractory (unresponsive) to conventional non-opioid medications. This therapeutic assistance contributes to easing the overall symptom load when symptoms become difficult to tolerate.

Quick Fact: Relief for Substantial Discomfort
Focus Area Pain of moderate to severe intensity
Therapeutic Benefit Supportive relief of physical discomfort
Relevant Contexts Acute post-surgical pain and chronic musculoskeletal pain

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Tradolgesic (Tramadol Hydrochloride) is designated for use only within specific population boundaries defined by regulatory authorities.

Contraindicated Populations

Use is contraindicated in several groups due to elevated risk. The medicine must not be used in children younger than 12 years of age or in adolescents under 18 following a tonsillectomy or adenoidectomy. It is also prohibited for patients in acute intoxication from alcohol or other central depressants, or in those with severe respiratory depression, acute asthma, or a known gastrointestinal obstruction like paralytic ileus. Use is strictly contraindicated if a patient is currently taking, or has recently taken (within 14 days), a Monoamine Oxidase Inhibitor (MAOI).

Use Restrictions and Special Considerations

Population Group Regulatory Status Status Context
Children/Adolescents (12–18) Not Recommended/Avoid Use If the patient has risk factors for breathing problems (e.g., severe lung disease, sleep apnea).
Severe Renal/Hepatic Impairment Not Recommended/Avoid Use Extended-release formulations are not recommended in severe kidney or liver disease.
Pregnancy Avoided/Conditional Use Only if the benefit outweighs the risk; prolonged use can cause Neonatal Opioid Withdrawal Syndrome.
Breastfeeding Not Recommended Due to the passage of the drug and its active metabolite into breast milk.
Older Adults (over 75) Use with Greater Caution Due to the increased risk of adverse events and slower drug elimination.

Underlying Condition Limits

Patients with conditions like epilepsy or a history of seizures are required to use the medicine with caution, and regulatory guidelines advise against prescribing to suicidal or addiction-prone patients. Regulatory documents define who is eligible based on these specific clinical and physiological constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns of Tradolgesic (Tramadol Hydrochloride) as specified in government regulatory documents.


Pharmacodynamic and Timing Constraints

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal contraindication, requiring a documented 14-day separation period from Tradolgesic administration. Combinations with other Central Nervous System (CNS) Depressants, including alcohol, carry a significant risk of profound sedation and respiratory depression due to additive pharmacodynamic effects. The concurrent use of Serotonergic Drugs (e.g., SSRIs, Triptans) or drugs that Lower the Seizure Threshold is associated with an enhanced risk of Serotonin Syndrome and seizures.

Pharmacokinetic and Exposure Modification

Interaction Type Interacting Substance Examples Regulatory Outcome
CYP2D6/3A4 Inhibition Fluoxetine, Ketoconazole Increases parent drug (Tramadol) plasma concentration.
CYP3A4 Induction Carbamazepine, St. John's Wort Reduces analgesic effect by increasing metabolism/clearance.

Population-Specific Interaction Notes

Regulatory documentation indicates that Ultra-Rapid CYP2D6 Metabolizers are at risk for life-threatening respiratory depression due to rapid conversion to the active M1 metabolite. Furthermore, the use of extended-release formulations is not recommended in individuals with severe hepatic impairment or severe renal impairment due to documented clearance concerns.

Mechanism of Action

Mechanism of Action: Dual Pathway Modulation

Tradolgesic (Tramadol Hydrochloride) operates through two primary, complementary mechanisms localized within the central nervous system (CNS) that modulate ascending and descending nociceptive transmission.

Central mu-Opioid Receptor Agonism

The active metabolite, O-desmethyltramadol (M1), functions as an agonist at the mu-Opioid Receptor (MOR). This interaction initiates a G-protein-coupled signal cascade that results in neuronal hyperpolarization, which reduces excitability and consequently modulates the ascending flow of nociceptive input through the spinal cord.

Monoaminergic Pathway Facilitation

Independently, the parent drug acts as an inhibitor of the Norepinephrine Transporter (NET) and the Serotonin Transporter (SERT). By preventing the reuptake of these neurotransmitters, their synaptic concentration is increased, which potentiates the descending inhibitory pathways that modulate central nociceptive transmission at the spinal dorsal horn, thus complementing the MOR effect.

Potency Constraint

The full potency of the mu-opioid component is mechanistically constrained by the activity of the hepatic enzyme CYP2D6, which is required to convert the parent drug into the active M1 metabolite. Diminished enzyme activity may result in a biologically constrained functional outcome at the MOR.

Dosage and Administration Information

Standard Usage Principles for Tradolgesic

Tradolgesic (tramadol hydrochloride) is administered through the oral route as tablets, capsules, or an oral solution, or via the parenteral route (intravenous, intramuscular, or subcutaneous injection) in a supervised setting. The standard usage is structured around two main formulation types that dictate frequency and dose ceilings.

Immediate-release (IR) forms are typically dosed every 4 to 6 hours as needed for relief, with the maximum total daily dose not exceeding 400 mg. For chronic pain management, extended-release (ER) forms are dosed once daily, starting at 100 mg, and generally have a lower maximum daily dose of 300 mg.

Instruction Category Standard Guidelines
Timing in relation to meals Oral forms may be taken with or without food.
Preparation Requirements Extended-release tablets/capsules must be swallowed whole and must not be chewed, crushed, or dissolved.
Older Adult Dosing For patients over 75 years of age, the total daily dose for IR forms should not exceed 300 mg.
Organ Impairment Rules Severe renal impairment necessitates increasing the IR dosing interval to 12 hours, with a maximum of 200 mg/day. ER forms are not recommended in severe renal or hepatic impairment.

The established instruction protocol mandates that use should be for the shortest duration consistent with treatment goals. Furthermore, the protocol requires that long-term use necessitates regular re-evaluation by a prescriber, and gradual dose tapering is advised when discontinuing the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tradolgesic

Evidence for Use in Moderate to Severe Acute Pain

This part summarizes the research base for Tradolgesic as it has been studied for the management of sudden, high-level physical discomfort. Research in this area includes short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that pool these findings. These studies are conducted during periods of increased symptom activity and involve comparing the medicine to a placebo (an inactive substance) in adult patients experiencing acute or disruptive episodes, such as pain that occurs right after a surgical procedure.

The research examined outcomes related to physical discomfort, with studies exploring how symptoms change over time. Findings describe patterns observed in the studies related to immediate symptomatic response, which is monitored by evaluating the amount of symptom change reported and the time until change was observed in the study populations. This evidence contributes to understanding symptom patterns over very short-term periods following administration. Research continues to explore patterns related to co-administration with other forms of pain management.

Evidence for Use in Persistent Chronic Pain Syndromes

The research base for using Tradolgesic in persistent symptoms consists mainly of Systematic Reviews and Meta-analyses. These analyses pool data from multiple clinical trials that focused on adult patients with conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis and chronic low back pain. Studies monitored patient-reported outcomes describing perceived discomfort and changes in daily functioning or activity level over defined time intervals.

Certainty remains low for this indication because the evidence quality varies across studies, with some initial trials having a notable potential for flaws in the way the original research was conducted. Some studies suggest that the measured symptomatic change may be small when compared to a larger change in reported symptoms. Additionally, the results apply only to the highly selected populations studied, meaning the data for certain groups remain insufficient.

Long-Term Research and Durability of Symptom Change

The maximum follow-up durations were limited in the trials assessed by regulatory bodies. Research has explored the stability of symptomatic patterns mainly over intermediate periods, meaning that the evidence provides context but not individual predictions for how symptoms may evolve over years of use.

Because the follow-up durations were limited, the status of long-term effects remains not fully established. Research has not determined whether the observed changes in symptoms remain consistent beyond the typical several-month observation period found in most chronic pain studies. This means that long-term symptomatic data after twelve months or more are still emerging.

Frequently Asked Questions (FAQ)

Common questions about Tradolgesic (FAQ)


Q: How quickly does Tradolgesic start to work for pain?

According to the official product information, the immediate-release form of Tradolgesic generally begins to work. The onset of action is typically observed within one hour after it is taken, with the maximum pain relief usually felt within 2 to 3 hours after administration.


Q: How long does one dose of Tradolgesic last?

The immediate-release forms of the medicine provide pain relief for approximately 6 hours. The extended-release forms, which are intended for chronic pain management, are formulated to provide sustained relief, typically lasting up to 24 hours with once-daily dosing.


Q: Why is Tradolgesic sometimes prescribed instead of other pain relievers?

Official information explains that Tradolgesic has a unique dual mechanism of action in the central nervous system. It works by combining effects at the mu-opioid receptor with the inhibition of the reuptake of the neurotransmitters norepinephrine and serotonin.


Q: What happens if I miss a dose of Tradolgesic?

Regulatory patient information states that if a dose is missed, it should be skipped entirely. The guidance is to take the next dose at the regularly scheduled time. It is important to avoid taking two doses at the same time to compensate for a missed dose.


Q: Can Tradolgesic be taken with common cold and flu medicines?

The official product labeling warns that co-administration with other Central Nervous System (CNS) depressants or serotonergic drugs is associated with a significant risk that warrants caution. This is due to an increased risk of severe side effects, including profound sedation or Serotonin Syndrome.


Q: Can young adults or teenagers use Tradolgesic for injuries?

Immediate-release formulations are generally suitable for individuals who are 12 years of age and older. However, official warnings caution against giving the extended-release form to patients under 18 years of age. Any use of this medicine must be determined by a healthcare provider.


Q: Why do doctors recommend taking Tradolgesic with food?

Regulatory documents state the medicine can be taken with or without food. Taking it with a meal may help minimize common gastrointestinal side effects, such as nausea and vomiting, according to official information.


Q: Does Tradolgesic lose its effectiveness over time (tolerance buildup)?

Official monitoring guidelines state that if long-term treatment is necessary, prescribers must perform regular re-evaluations. Tolerance is a potential risk associated with the long-term use of opioids, meaning the pain-relieving effect may diminish over time.


Q: What's the difference in how Tradolgesic works compared to an NSAID?

Unlike Nonsteroidal Anti-inflammatory Drugs (NSAIDs) which often target local inflammation, Tradolgesic is a centrally acting analgesic. Its mechanism involves direct action on the brain and spinal cord to alter the body's perception of pain. The medicine is not classified as an anti-inflammatory drug.


Q: Has Tradolgesic been studied a lot in clinical trials?

Official regulatory reviews indicate that the medicine has been studied in numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies have explored its effectiveness for both acute and chronic pain conditions.


Q: What is the average time it takes for Tradolgesic to clear your system?

Regulatory pharmacokinetic data indicates that the medicine's elimination half-life is typically around 5 to 7 hours. Based on its half-life, the majority of the medicine is expected to be eliminated from the body within a few days.


Q: Is Tradolgesic used for nerve pain, or only muscle and joint pain?

The medicine is officially indicated for the management of moderate to severe pain in general. While studies often focus on conditions like osteoarthritis, its dual action mechanism is thought to affect pain pathways, including those involved in nerve transmission.


Q: Why do some people say Tradolgesic helps them sleep better?

One of the common side effects listed in the regulatory documents is somnolence, which means drowsiness or sleepiness. This is a central nervous system depressant effect that may result in feelings of sleepiness.


Q: Are there generic versions of Tradolgesic available?

Yes, the active ingredient in Tradolgesic, Tramadol Hydrochloride, is available from various manufacturers in multiple generic formulations, in addition to the brand-name product.


Q: What are the signs of a serious allergic reaction to Tradolgesic?

Serious allergic reactions, such as anaphylaxis, are rarely listed in official labeling. Warning signs can include hives or rash, difficulty breathing or swallowing, and swelling of the face, throat, tongue, lips, or extremities.


Q: Can you take Tradolgesic if you have liver or kidney problems?

The medicine is not recommended for individuals with severe liver or kidney impairment due to clearance concerns. For patients with less severe issues, the official guidance requires that the dosing interval may need to be extended.


Q: Is Tradolgesic safe to take if you have a history of heart issues?

Official warnings note that the medicine can cause cardiovascular changes, including a drop in blood pressure upon standing (postural hypotension). Due to the potential for these effects, caution is warranted for individuals with existing heart conditions.


Q: What if I take my other medicine too close to my Tradolgesic dose?

Taking medicines that interact too close together can elevate the risk of adverse effects. It is important to follow the prescribed dosing interval and avoid concurrent use with any contraindicated or interacting drugs.


Q: Does Tradolgesic affect birth control pills?

Regulatory warnings mention that the chronic use of opioids can affect the body's hormone-producing systems, potentially leading to androgen deficiency. This may manifest as menstrual irregularities, such as a lack of periods (amenorrhea).


Q: Can Tradolgesic interact with herbal supplements like St. John's Wort?

Yes, the official labeling specifically lists St. John’s Wort as a substance that may cause an interaction. It acts as a CYP3A4 inducer, which means it can increase how quickly the body metabolizes the medicine, potentially reducing its pain-relieving effect.


Q: What is the primary mechanism of action of Tradolgesic?

The medicine works through two complementary mechanisms in the central nervous system. Its active metabolite binds to the mu-opioid receptor, and the parent drug inhibits the reuptake of the neurotransmitters norepinephrine and serotonin. This dual action modifies the transmission of pain signals.


Q: Is Tradolgesic considered a short-term or long-term pain medication?

Official administration protocol states that the medicine should be used for the shortest duration that is consistent with treatment goals. If long-term use is necessary, the protocol mandates regular re-evaluation by a prescriber.


Q: What type of pain relief category does Tradolgesic fall into?

The medicine is officially classified as a centrally acting synthetic opioid analgesic. It is designated for the management of moderate to severe pain, which is a category used to define its therapeutic role.


Q: Is it possible to become dependent on Tradolgesic?

Official warnings highlight the risk for opioid addiction, abuse, and misuse. Additionally, the medicine can cause physical dependence with long-term use. For this reason, official guidance advises that the dose be gradually reduced when discontinuing treatment.


Q: Why is Tradolgesic not recommended for people with asthma?

The medicine is formally contraindicated (prohibited) in patients with acute or severe bronchial asthma. This is because Tradolgesic carries a significant risk of life-threatening respiratory depression, which is a major concern for individuals with impaired breathing.


Q: Does Tradolgesic come in different strengths?

Yes, the official product labeling confirms that Tradolgesic is supplied in various strengths and formulations. These include both the immediate-release tablets and capsules, and the extended-release forms.


Q: Can I take Tradolgesic if I am trying to get pregnant?

Official guidance advises that the medicine should be avoided or used only conditionally during pregnancy. It is prescribed only if the benefit to the mother outweighs the risk, as prolonged use can cause Neonatal Opioid Withdrawal Syndrome in newborns.


Q: What evidence supports the use of Tradolgesic for chronic back pain?

The research evidence includes studies for chronic low back pain. However, official reviews note that while symptomatic change is observed, the certainty remains low for this indication, and the measured symptomatic change may be small compared to the change reported by the patient.


Q: Can I crush or split the Tradolgesic tablets?

Extended-release tablets and capsules must not be crushed, chewed, or dissolved. Altering these forms can cause a rapid, uncontrolled release of the medicine, which may increase the risk of serious side effects.


Q: How does Tradolgesic specifically target pain signals?

Official documents state that the medicine works by modulating the flow of pain signals. This is achieved by reducing the excitability of neurons (nerve cells) and by potentiating the descending inhibitory pathways, which naturally reduce the transmission of pain in the spinal cord.


Q: Is it important to take Tradolgesic at the exact same time every day?

The extended-release formulation is intended for once-daily use and should be taken at a consistent time each day to maintain steady pain control. Immediate-release forms are taken only as needed, with a minimum interval between doses.


Q: Does Tradolgesic have an anti-inflammatory effect?

The medicine’s official mechanism of action is focused on its central analgesic effects (opioid receptor binding and neurotransmitter reuptake inhibition). It is not classified as an anti-inflammatory drug and does not work by inhibiting inflammatory enzymes.

How should Tradolgesic be stored and disposed of?

How to Store and Dispose of Tradolgesic?

Storage and disposal requirements for Tradolgesic (tramadol hydrochloride) are defined by official labeling to ensure product integrity and prevent serious risks like accidental poisoning or misuse.


Storage Conditions

Requirement Details
Temperature Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F).
Packaging Keep the medicine in its original container and ensure the cap is tightly closed.
Child Safety Store securely, out of the sight and reach of children and pets, due to the risk of fatal overdose from accidental ingestion.

Disposal Instructions

Unused or expired Tradolgesic must be handled as a high-risk medication. The preferred method for disposal is to use a drug take-back program or mail-back envelope. If a take-back option is not immediately available, the official labeling for this opioid permits flushing the tablets down the toilet immediately to prevent accidental access.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tradolgesic found in:

A-Z Index: